نتایج جستجو برای: myelodysplastic syndromes
تعداد نتایج: 86513 فیلتر نتایج به سال:
Partial or complete deletion of the long arm of chromosome 5 [del(5q)], with or without additional karyotypic abnormalities, is present in 10-15% of myelodysplastic syndromes (MDS). Anemia in these MDS responds less often to erythroblastic stimulating agents. However, immunomodulatory, anti-cytokine, and anti-angiogenic agent Lenalidomide (CC5013, Revlimid®) leads to red blood cells transfusion...
BACKGROUND AND OBJECTIVES In contrast with hematologic malignancies in which the value of immunophenotypic studies is well established, information on the immunophenotypic characteristics of myelodysplastic syndromes (MDS) is scanty. The main goal of the present study was to explore the immunophenotypic differences between patients with MDS and normal individuals, including changes in distribut...
The comet assay (single-cell gel electrophoresis) has been established as a simple, rapid, flexible and sensitive method of detecting DNA damage in single cells(1,2). Cells embedded in agarose on a microscope slide are lysed with detergent. Electrophoresis at high pH results in structures resembling comets, observed by fluorescence microscopy; the intensity of the comet tail relative to the hea...
In 1900, Leube described a patient with severe megaloblastic anemia, preceding the development of overt leukemia. This case was followed by similar reports of patients characterized by cytopenia, dysmaturation of marrow precursors, an increase of marrow blasts and a significant risk of evolving to acute myeloid leukemia. The first classification of the myelodysplastic syndromes published in 198...
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for progression, suggest that myelodysplastic syndromes encompass a multitude of d...
Cancer development is a dynamic process during which the successive accumulation of mutations results in cells with increasingly malignant characteristics. Here, we show the clonal evolution pattern in myelodysplastic syndrome (MDS) patients receiving supportive care, with or without lenalidomide (follow-up 2.5-11 years). Whole-exome and targeted deep sequencing at multiple time points during t...
Myelodysplastic syndromes (MDS) are a diverse group of hematopoietic disorders characterized by dysplasia, peripheral cytopenias, and risk of progression to acute myeloid leukemia and death. In patients who are ineligible for potentially curative hematopoietic stem cell transplantation (HSCT), approved therapies such as lenalidomide, azacitidine, and decitabine are available for those who previ...
of risk. This importance is particularly stressed if the prognostic variability and aggressive nature of the currently available curative treatment options is taken into account, especially when considering the advanced age of the majority of patients. Although the French-American-British (FAB) classification has been relatively effective for categorizing MDS patients since 1982,1 its limitatio...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید